CLSD
Clearside Biomedical·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 1
Bearish signal 1
EPS Beats Expectation
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About CLSD
Clearside Biomedical, Inc.
A company developing opthalmic therapeutic products
900 North Point Parkway, Suite 200, Alpharetta, GA 30005
--
Clearside Biomedical, Inc., was incorporated in Delaware on May 26, 2011. The company is a late-stage clinical biopharmaceutical company that develops first-in drug therapies to treat blinding diseases of the eye. The company's current product candidates focus on addressing diseases affecting the retina and choroid, especially macular edema, and are injected into the suprachoroidal space using its proprietary SCS microinjector.
Company Financials
EPS
CLSD has released its 2025 Q2 earnings. EPS was reported at -0.06, versus the expected -0.1, beating expectations. The chart below visualizes how CLSD has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
CLSD has released its 2025 Q2 earnings report, with revenue of 492.00K, reflecting a YoY change of 446.67%, and net profit of -4.50M, showing a YoY change of 40.81%. The Sankey diagram below clearly presents CLSD's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
